Cancer Family
Mesenchymal Cell Neoplasm
CI-CAN-00000027Explore in graph →
Non-malignant413 active trials10 approved drugs208 evidence items
- NCIt
- C7059
Loading cancer entity…
Cancer Family
CI-CAN-00000027Explore in graph →
Clinical trials
1,848 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02847559 | Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | completed | Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05395741 | Regorafenib in Patients With Refractory Primary Bone Tumors(Regbone) | completed | Phase 1 / Phase 2 | 30 | Institute of Mother and Child, Warsaw, PolandOTHER | 1 | Aug 21, 2026 |
| clinicaltrials |
| NCT00407433 | Clinical Studies of Gemcitabine-Oxaliplatin | completed | Phase 2 | 156 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03556384 | Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) | completed | Phase 2 | 23 | Adam Burgoyne, MD, PhDOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT02389244 | A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas(REGOBONE) | completed | Phase 2 | 163 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03006848 | A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma | completed | Phase 2 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT06668987 | A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma | completed | Phase 1 / Phase 2 | 10 | Heron Neutron Medical Corp.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT04807816 | Targeting ATR in Soft-tissue Sarcomas(TARSARC) | completed | Phase 2 | 58 | Institut BergoniéOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03944304 | Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. | completed | Phase 2 | 40 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04633122 | A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib | completed | Phase 2 | 108 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02945800 | Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma | completed | Phase 2 | 59 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05152173 | Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis | completed | Phase 2 | 176 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05218499 | Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | completed | Phase 2 / Phase 3 | 400 | Boehringer IngelheimINDUSTRY | 22 | Mar 2, 2026 | clinicaltrials |
| NCT01207492 | Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor | completed | Phase 2 | 17 | Andrew J. Wagner, MD, PhDOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04794127 | Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.(TRABEPIO) | completed | Phase 2 | 10 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06562673 | Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma(IACE-OS) | completed | Phase 1 / Phase 2 | 10 | Shanghai 6th People's HospitalOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06322342 | Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent | completed | Phase 2 | 18 | Reveal Pharmaceuticals Inc.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT03526679 | Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma(LEADER) | completed | Phase 1 / Phase 2 | 30 | National Taiwan University HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06439420 | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial(CBT-I in PBT) | completed | Phase 2 | 70 | Virginia Commonwealth UniversityOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT03425279 | CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma | completed | Phase 1 / Phase 2 | 245 | BioAtla, Inc.INDUSTRY | 3 | Sep 23, 2025 | clinicaltrials |
| NCT04258956 | A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy(AXAGIST) | completed | Phase 2 | 58 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT03899805 | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | completed | Phase 2 | 57 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT01907607 | Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib(CYCLIGIST) | completed | Phase 2 | 29 | Institut BergoniéOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT05080790 | Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma(DiTuSarc) | completed | Phase 2 | 7 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT04282980 | A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) | completed | Phase 2 | 39 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT02428192 | Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04095221 | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | completed | Phase 1 / Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02401815 | CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 51 | Cogent Biosciences, Inc.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT02249949 | Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery | completed | Phase 2 | 15 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT00780494 | Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma | completed | Phase 2 | 35 | Stanford UniversityOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03241745 | A Study of Nivolumab in Selected Uterine Cancer Patients | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06115408 | Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma | completed | Phase 2 / Phase 3 | 40 | Ain Shams UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT03023124 | Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor(STRADA) | completed | Phase 2 | 23 | Italian Sarcoma GroupNETWORK | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01117844 | Proton Radiation For Meningiomas and Hemangiopericytomas | completed | Phase 1 / Phase 2 | 53 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT03840772 | Eribulin in Advanced Solitary Fibrous Tumor(ERASING) | completed | Phase 2 | 16 | Italian Sarcoma GroupNETWORK | 1 | Sep 20, 2024 | clinicaltrials |
| NCT01863745 | Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment | completed | Phase 2 | 15 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 19, 2024 | clinicaltrials |
| NCT01294202 | A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST | completed | Phase 2 | 26 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02978859 | Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas | completed | Phase 2 | 29 | Columbia UniversityOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT00290251 | Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914 | completed | Phase 2 | 72 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Jul 15, 2024 | clinicaltrials |
| NCT03320330 | Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 26 | Children's Oncology GroupNETWORK | 1 | Jul 15, 2024 | clinicaltrials |
| NCT05349643 | A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT | completed | Phase 2 | 20 | AmMax Bio, Inc.INDUSTRY | 3 | Jul 5, 2024 | clinicaltrials |
Data updated 20 days agoSource updated Sep 9, 2026source: clinicaltrials